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Abstract
We have systematically investigated how vascular smooth muscle a1-adreno-
ceptor activation impacts endothelium-mediated vasodilation in isolated, myo-
genically active, rat cremaster muscle 1A arteries. Cannulated cremaster
arteries were pressurized intraluminally to 70 mmHg to induce myogenic
tone, and exposed to vasoactive agents via bath superfusion at 34°C. Smooth
muscle membrane potential was measured via sharp microelectrode recordings
in pressurized, myogenic arteries. The a1-adrenergic agonist phenylephrine
(25–100 nmol/L) produced further constriction of myogenic arteries, but did
not alter the vasorelaxant responses to acetylcholine (0.3 lmol/L), SKA-31 (an
activator of endothelial Ca2+-dependent K+ channels) (3 lmol/L) or sodium
nitroprusside (10 lmol/L). Exposure to 0.25–1 lmol/L phenylephrine or
1 lmol/L norepinephrine generated more robust constrictions, and also
enhanced the vasodilations evoked by acetylcholine and SKA-31, but not by
sodium nitroprusside. In contrast, the thromboxane receptor agonist U46619
(250 nmol/L) dampened responses to all three vasodilators. Phenylephrine
exposure depolarized myogenic arteries, and mimicking this effect with 4-ami-
nopyridine (1 mmol/L) was sufficient to augment the SKA-31-evoked vasodi-
lation. Inhibition of L-type Ca2+ channels by 1 lmol/L nifedipine decreased
myogenic tone, phenylephrine-induced constriction and prevented a1-adrener-
gic enhancement of endothelium-evoked vasodilation; these latter deficits were
overcome by exposure to 3 and 10 lmol/L phenylephrine. Mechanistically,
augmentation of ACh-evoked dilation by phenylephrine was dampened by
eNOS inhibition and abolished by blockade of endothelial KCa channels. Col-
lectively, these data suggest that increasing a1-adrenoceptor activation beyond
a threshold level augments endothelium-evoked vasodilation, likely by trigger-
ing transcellular signaling between smooth muscle and the endothelium. Phys-
iologically, this negative feedback process may serve as a “brake” to limit the
extent of vasoconstriction in the skeletal microcirculation evoked by the ele-
vated sympathetic tone.
Introduction
Changes in tissue blood flow are largely dependent upon
the intraluminal diameter of small resistance arteries,
which is jointly controlled by the myogenic reactivity of
vascular smooth muscle, vasoactive molecules generated
in the adjacent endothelium and the activity of sympa-
thetic nerves innervating the arterial wall (Segal 2005;
Bagher and Segal 2011; Westcott and Segal 2013). Each of
these control processes depends upon diverse pathways
and mechanisms at the cellular level, however, it remains
poorly understood how these control processes interact
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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with one another, as intraluminal diameter will ultimately
be determined by the sum of their actions.
Several studies have provided compelling evidence that
the vascular endothelium directly communicates with the
adjacent smooth muscle via electrical and chemical signal-
ing (e.g., myo-endothelial coupling)(Busse et al. 2002;
Edwards et al. 2010; Garland et al. 2011; Billaud et al.
2014), and related studies have demonstrated that signal-
ing events originating in vascular smooth muscle can be
detected in coupled endothelial cells (Dora et al. 1997;
Yashiro and Duling 2000; Isakson et al. 2007; Nagaraja
et al. 2012; Nausch et al. 2012; Garland et al. 2017). In
particular, reports from Duling, Dora and coworkers have
indicated that hormonal activation of vascular smooth
muscle (VSM) a1-adrenoceptors in resistance arteries can
lead to elevated intracellular Ca2+ in the adjacent
endothelial layer (Dora et al. 1997; Yashiro and Duling
2000; Isakson et al. 2007; Garland et al. 2017), which may
subsequently impact endothelial function and regulation
of vascular tone. In this study, we have hypothesized that
concurrent a1-adrenoceptor activation will either posi-
tively or negatively influence endothelium-dependent
vasodilation, and this impact will depend upon the degree
of a1-adrenoceptor activation (i.e., magnitude/direction of
effect driven by the concentration of a1-adrenoceptor
agonist). This hypothesis was examined by investigating
the influence of VSM a1-adrenoceptor activation on the
regulation of intraluminal diameter by endothelium-
dependent vasodilators in isolated, myogenically active rat
skeletal muscle arteries. Experimentally, such qualitative
effects would be observed as a quantitative enhancement
or impairment of evoked, endothelium-dependent vasodi-
lation in the presence vs. the absence of a1-adrenoceptor
activation. Such a1-mediated effects on endothelial func-
tion could arise from altered intracellular Ca2+ signaling
(Dora et al. 1997; Yashiro and Duling 2000; Isakson et al.
2007), and/or responsiveness of VSM to vasoactive signals
from the endothelium (e.g., changes in the sensitivity of
VSM to endothelium-derived signals).
The results of our study demonstrate the a1-adrenergic
agonists phenylephrine and noradrenaline, but not the
thromboxane receptor agonist U46619, significantly
enhanced endothelium-dependent vasodilation in
response to acetylcholine (ACh) and the KCa channel acti-
vator SKA-31, whereas the vasodilatory response to
sodium nitroprusside was unaffected in the presence of
a1-adrenoceptor activation. This observed enhancement
of ACh- and SKA-31-mediated dilations by a1-adrenocep-
tor agonist occurred in a concentration-dependent man-
ner, and required intact eNOS and/or endothelial KCa
channel activities. Mechanistically, a1-adrenoceptor
evoked changes in vascular smooth muscle (VSM) Ca2+
levels, as revealed by L-type Ca2+ channel inhibition with
nifedipine. Increased membrane electrical resistance also
appears to contribute to the positive effect of a1-adrener-
gic signaling on ACh and SKA-31-mediated dilation. Col-
lectively, these results provide new insights describing
how graded activation of VSM a1-adrenoceptors is able to
modulate endothelium-mediated vasodilation. Function-
ally, this intercellular communication may underlie a
novel negative feedback mechanism in skeletal muscle
resistance arteries to limit the active decrease in intralu-
minal diameter driven by a1-adrenoceptor signaling and/
or myogenic contraction.
Methods and Materials
Isolated vessel preparation
The experimental protocols used in this study were
approved by the University of Calgary Animal Care Com-
mittee, and conform to the guidelines for the care and
use of laboratory animals established by the Canadian
Council on Animal Care and the Guide for the Care and
Use of Laboratory Animals (NIH, 8th edition, 2011).
Male Sprague-Dawley rats (225–250 g body weight) were
obtained from Charles River Laboratories and housed
under standard conditions (i.e., 12 h day/light cycle,
22°C) with continuous access to food and water. Rats
were injected intraperioneally with sodium pentobarbital
(50 mg/kg) to induce surgical anesthesia (i.e., stage 3, loss
of blink reflex), and cremaster muscles were then surgi-
cally removed and placed in a cooled (4°C) dissection
chamber containing Krebs’ buffer (115 NaCl, 5 mmol/L
KCl, 25 mmol/L NaHCO3, 1.2 mmol/L MgCl2,
2.5 mmol/L CaCl2, 1.2 mmol/L KH2PO4 and 10 mmol/L
D-glucose); pH was adjusted to 7.4 with 1 N NaOH (Mei-
ninger et al. 1991; Sheng et al. 2009). Euthanasia was
completed by an overdose administration of sodium pen-
tobarbital (150 mg/kg, I.P.). Following isolation, cremas-
ter 1A arteries were cannulated on glass pipettes fitted in
a pressure myography chamber (Living Systems, Burling-
ton, VT) and the vessel lumen was filled with Krebs’ buf-
fer containing 1% bovine serum albumin, pH was
adjusted to 7.4. The cannulated vessel/chamber apparatus
was placed on the stage of an inverted microscope, and
one cannula end was closed and the other connected to a
hydrostatic pressure column. The vessel was superfused
with Krebs’ buffer at a constant flow of 7 mL/min, using
a peristaltic pump and suction line. Bath solution was
gassed with 95% air/5% CO2 and maintained at 34°C.
The intraluminal pressure of cannulated vessels was
increased in a step-wise manner under no-flow conditions
and then maintained at 70 mmHg; vessels typically devel-
oped myogenic tone within 15–20 min. Intraluminal ves-
sel diameter was continuously tracked using a video
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camera-based imaging system (IonOptix, Milton, MA).
Drugs were added to the bath via the peristaltic pump.
Note that changing the experimental order in which
vasodilators were applied to arteries did not change the
magnitude of observed responses to a given dilator.
Drug-induced changes in arterial intraluminal diameter
(i.e., inhibition of myogenic tone, expressed in microns)
were calculated as the difference in steady-state diameter
in the presence of a given vasodilator (Ddrug) and the
intraluminal diameter under baseline conditions (Dbasal)
measured immediately prior to a given drug exposure.
Thus,
Inhibition of Myogenic ContractionðlmÞ
¼ Ddrug Dbasal;
where Ddrug = intraluminal diameter in the presence of a
given vasodilator (e.g. ACh or SNP), Dbasal = intraluminal
diameter under basal myogenic tone at 70 mmHg. When
vasodilatory responses were measured in the presence of
myogenic tone + a constrictor agent (i.e. PE, NE or
U46619), the Dbasal value was calculated at the new base-
line diameter observed in the presence of the constrictor,
immediately prior to each vasodilatory response.
Membrane Potential Recordings
Sharp microelectrodes were fabricated from borosilicate
capillaries containing an internal filament (1.0 mm OD,
0.58 mm ID) using a Sutter P-97 electrode puller. Micro-
electrodes were filled with 1 mol/L KCl and had tip resis-
tances of 100–150 MΩ when placed in the bath solution.
Voltage offsets for the microelectrodes were zeroed using
the microelectrode amplifier (NPI model SEC-05X). Iso-
lated cremaster 1A arteries were cannulated and pressur-
ized to 60 mmHg, as described above. Following the
development of myogenic tone, a microelectrode was
impaled into the vessel wall and smooth muscle mem-
brane potential (Vm) was monitored continuously and
recorded on a computer using LabView-based acquisition
software. A cell impalement was considered to be success-
ful if a sharp negative deflection in Vm was observed
upon insertion of the microelectrode into the outer
smooth muscle layer and a stable recording of Vm was
obtained for >1 min. Once a baseline Vm was established,
the amplifier was switched to current clamp mode and
three negative current pulses of increasing magnitude
(range, 30 to 240 pA, 2 sec duration) were injected.
Corresponding deflections in Vm from the baseline were
recorded and the amplitudes were plotted vs. injected
current step size. The calculated slope of the relation (i.e.,
Vm vs. current step size) yielded the electrical resistance
of the smooth muscle membrane (Rm). Following
measurements of Vm and Rm under control conditions,
the bath solution was switched to one containing 1 lmol/
L phenylephrine, which caused the artery to constrict. In
some instances, microelectrode impalements were main-
tained and continuous recordings of Vm were obtained;
however, the PE-induced constriction typically led to loss
of the impalement, necessitating the reinsertion of the
microelectrode. Once a stable basal Vm was achieved in
the presence of PE, current injections were repeated and
Rm calculated as described above. In a few instances,
measurements of smooth muscle Vm and Rm were
obtained following PE washout and recovery of the artery
to basal myogenic conditions.
Reagents
Acetylcholine chloride, EGTA (ethylene glycol-bis(2-ami-
noethylether)-N,N,N’,N’-tetraacetic acid), Phenylephrine
hydrochloride ((R)-(-)-1-(3-hydroxyphenyl)-2-methylami-
noethanol hydrochloride), (-)Norepinephrine bitartrate
salt, 4-AP (4-aminopyridine), SNP (sodium nitroprus-
side), DMSO (dimethyl sulfoxide), Nifedipine (1,4-dihy-
dro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicar-
boxylic acid dimethyl ester), Pinacidil (N-cyano-N0-4-
pyridinyl-N″-(1,2,2-trimethylpropyl)guanidine monoh
ydrate), U46619 (5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-
hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]hept-5-yl]-5-hepte-
noic acid, and all required chemicals to prepare
physiological solutions were purchased from Sigma-
Aldrich (Oakville, ON, Canada). Euthanyl (sodium pento-
barbital, 250 mg/mL) was purchased from Bimeda-MTC
Animal Health Inc, Cambridge, ON, Canada. SKA-31
(naphtho [1, 2-d] thiazole-2-ylamine) was synthesized as
previously described (Sankaranarayanan et al. 2009).
SKA-31, pinacidil and nifedipine were prepared as
10 mmol/L stock solutions in DMSO and then diluted
directly into the external bath solution. The final concen-
tration of DMSO reaching the tissue was typically 0.02%
(vol/vol) or less. In preliminary experiments, we observed
that a considerably higher concentration of DMSO (0.2%
v/v final) had no effect on either basal myogenic tone or
the responsiveness of cremaster arteries to vasodilatory
agents (n = 2, data not shown).
Statistical analysis
Data are presented as mean  SEM for n arteries
obtained from N different animals. Often, only one artery
was examined per animal, due to the lengthy duration of
the experimental protocol. For each artery, functional
responses to pharmacologic agents were first obtained
under control conditions and then in the presence of a
stated treatment (e.g., 1 lmol/L phenylephrine exposure).
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Each vessel thus served as its own control for a given
manipulation. The difference in the magnitude of
response to a given agent under control and treatment
conditions (i.e., R2 - R1) was then calculated and pre-
sented graphically, as described in Figure 1B. In some
cases, a calculated set of differences was analyzed using a
one sample t-test (SigmaPlot ver12) to determine if the
mean was statistically different than zero (see Figs. 3, 6B
and 8C). For other data, a statistically significant differ-
ence for the same stimulus under two experimental con-
ditions was evaluated, using either a Student’s unpaired
t-test (see Fig. 8B) or a one-way ANOVA, followed by a
Tukey post hoc test. A calculated P < 0.05 was taken to
signify statistical significance.
Results
The a1-adrenoceptor agonist phenylephrine
selectively enhances endothelium-
dependent responses in myogenically active
rat cremaster arteries
To examine the interaction between endothelium-depen-
dent regulation of intraluminal diameter in a small resis-
tance artery in the absence and presence of
a1-adrenoceptor stimulation, we utilized cannulated, myo-
genically active rat cremaster arteries. As displayed in Fig-
ure 1A, brief exposure to the endothelium-dependent
dilator acetylcholine (ACh), at a concentration (0.3 lmol/
L) predicted to produce ~60% dilation(Sheng et al. 2009),
reversibly inhibited myogenic tone at 70 mmHg, leading
to an increase in intraluminal diameter of 55.8  6.6 lm
(n = 67 arteries). A similar result was observed for
3 lmol/L SKA-31, a small molecule activator of endothe-
lial small and intermediate-conductance, Ca2+-activated
K+ channels (KCa 2.3 and KCa 3.1, respectively) (change
in intraluminal diameter from baseline = 47.2  5.8 lm,
n = 67). The concentration of SKA-31 used experimen-
tally approximated its EC50 value in rat cremaster arteries
(Mishra et al. 2015). Note that the SKA-31 solvent (i.e.
DMSO) alone had no effects on baseline myogenic tone
at bath concentrations ≥ 10-fold higher than normally
used (data not shown). The nitrovasodilator sodium
nitroprusside (SNP), which acts directly on VSM to inhi-
bit myogenic tone(Rubanyi and Vanhoutte 1985; Brizzo-
lara and Burnstock 1991; Mishra et al. 2015), was used as
an internal control and increased intraluminal diameter
by 46.8  4.9 lm (n = 67). The experimentally deter-
mined EC50 value for SNP-evoked vasodilation in our
vessels was 6.0 lmol/L (data not shown). When normal-
ized to the total amount of active myogenic constriction
generated in these arteries (85.6  8.7 lm, n = 67), the
percentage inhibition of myogenic tone evoked by ACh,
SKA-31 and SNP was calculated to be 65.2%, 55.1% and
54.7%, respectively. The procedure for this latter calcula-
tion is described in detail elsewhere (Mishra et al. 2015).
In the presence of a low concentration of the a1-adre-
nergic agonist phenylephrine (PE, 25 nmol/L), which
itself caused a further reduction in intraluminal diameter,
dilations in response to ACh, SKA-31 and SNP were lar-
gely unchanged. However, when the same artery was
exposed to a higher concentration of PE (1 lmol/L),
intraluminal diameter decreased further and ACh and
SKA-31 now evoked markedly larger dilations compared
with those observed in the presence of 25 nmol/L PE. In
contrast, 1 lmol/L PE exposure did not change the dila-
tory response to SNP. Control experiments further
demonstrated that repeated exposures to ACh, SKA-31
and SNP (3 for each agent) produced stable vasodilatory
responses over a period of ~4 h, in which exposures to a
given agent were separated by ~60 min (data not shown).
Washout of PE from the bath always resulted in return of
intraluminal diameter to a level approximating the initial
baseline value, strongly suggesting that myogenically
active arteries retained their functional integrity and
responsiveness throughout the protocol.
Systematic analysis of a1-adrenergic effects
on evoked vasodilation by endothelium-
dependent and -independent agents
The upper panel in Figure 1B depicts the possible alter-
ations in endothelium-dependent vasodilation in the pres-
ence of VSM a1-adrenoceptor activation (i.e., augmented,
impaired or unchanged), as identified by the measurable
differences in dilatory responses (i.e., R2–R1) in the pres-
ence and absence of an a1-adrenergic agonist (e.g.,
phenylephrine, PE). The plot in Figure 1B further illus-
trates how these quantified differences in vasodilatory
responses may change with increasing concentrations of
the a1-adrenergic agonist (for simplicity, only monophasic
relations are shown). Revisiting the data presented in Fig-
ure 1A, two points are immediately evident: 1) a1-adre-
noceptor activation promotes an augmentation of
endothelium-evoked dilation (i.e. R2–R1), and 2) this a1-
adrenergic facilitation of evoked dilation occurs in a con-
centration-dependent manner. We further speculate that
these observed phenomena may follow the prediction
described by the plotted blue symbols in Figure 1B.
The observed enhancement of endothelium-dependent
vasodilation by a1-adrenoceptor signaling largely repro-
duces the basic observation described by Duling and col-
leagues(Dora et al. 1997, 2003; Yashiro and Duling 2000),
and was investigated in a more extensive manner by
examining the vasodilatory effects of the endothelium-
dependent dilators ACh (0.3 lmol/L) and SKA-31
2018 | Vol. 6 | Iss. 9 | e13703
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(3 lmol/L) and the smooth muscle agent SNP (10 lmol/
L) in the absence and presence of 25, 100, 250, and
1000 nmol/L PE. This range of PE concentrations would
be expected to produce increasing activation of VSM
a1-adrenoceptors in cremaster arteries(Faber 1988;
Jackson et al. 2008; Moore et al. 2010a), which would be
reflected functionally by elevated levels of contraction
(i.e., reductions in intraluminal diameter) in myogenically
active arteries. Differences in the magnitude of stimulus-
evoked dilation could then be measured, using the
Figure 1. Panel (A) shows a representative tracing of stimulus-evoked dilations in a single cannulated cremaster artery in the absence and
presence of phenylephrine (PE). Addition of acetylcholine (ACh, 0.3 lmol/L), SKA-31 (3 lmol/L), or SNP (10 lmol/L) produced rapid and
reversible increases in intraluminal diameter, as indicated by horizontal bars above the tracing. Exposures to vasodilatory agents were then
repeated in the presence of either 25 nmol/L PE or 1 lmol/L PE, followed by washout (W/O) of PE from the bath, as shown by the horizontal
bars below the tracing. Superfusion with a nominally Ca2+-free Krebs’ buffer containing 2 mmol/L EGTA was performed to obtain the maximal
passive intraluminal diameter at 70 mmHg. The tracing is representative of 6 cremaster arteries subjected to the same experimental protocol.
The schematic in panel (B) depicts the hypothetical influence of vascular smooth muscle a1-adrenoceptor activation on stimulus-evoked dilation
of a myogenically active skeletal muscle artery. The idealized tracings in the upper panel depict reversible, stimulus-induced vasodilatory
responses (i.e. change in intraluminal diameter from the basal level) in a myogenic artery and how the amplitude of these primary responses
may be hypothetically altered in the presence of an a1-adrenoceptor agonist (e.g. PE). The pair of tracings on the left illustrates a positive
influence of PE on the amplitude of evoked dilation (R2 response, blue trace) compared with the control (R1, black trace), as indicated by the
larger vasodilation (i.e., R2 > R1). The right-hand tracings show a negative effect of PE on the induced vasodilatory response (i.e., R2 < R1,
green trace), while the middle tracings demonstrate no change in the amplitude of evoked dilation in the presence of PE (R2 = R1, red trace).
A plot of the relative changes in the amplitude of evoked dilation  PE (i.e. R2–R1) illustrates these three possible influences of PE (i.e.,
positive effect, blue symbols; no effect, red symbols; negative effect, green symbols) and how they may change with increasing VSM
a1-adrenoceptor activation.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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strategy depicted in Figure 1B (i.e., R2–R1) and plotted
versus the magnitude of PE-induced contraction at the
indicated concentration. Pharmacologically, PE-stimulated
contraction correlates with a1-adrenoceptor activation/oc-
cupancy in VSM (Ruffolo 1987). Quantitatively, PE-
dependent decreases in intraluminal diameter at
70 mmHg ranged from 10 lm at 25 nmol/L PE up to
~60 lm at 1 lmol/L PE. This analytical approach thus
allowed us to evaluate how a relative change in stimulus-
evoked dilation (i.e., R2–R1) correlated with the magni-
tude of PE-induced constriction (i.e., a reflection of VSM
a1-adrenoceptor activation). The scatter plot displayed in
Figure 2A shows that ACh-evoked dilation was clearly
augmented in the presence of either 250 nmol/L or
1 lmol/L PE (denoted by symbols appearing above the
zero difference line), but not in the presence of either 25
or 100 nmol/L PE (i.e., symbols clustered near the zero
difference line). Note that each symbol in the plot repre-
sents a measurement from an individual artery. A similar
pattern of results was observed for SKA-31-induced dila-
tions in the absence and presence of PE exposure
(Fig. 2B). In contrast, SNP-evoked dilations remained
unchanged over the same range of PE concentrations
(Fig. 2C), indicating that the observed PE-mediated effect
was selective for endothelium-mediated vasodilatory
responses.
For ACh, SKA-31, and SNP, the relative differences in
evoked dilation (i.e. R2–R1 data) were further used to
calculate average values at each concentration of PE
exposure. As presented in Figure 3, calculated mean dif-
ferences in ACh responses in the presence of 25 and
100 nmol/L PE are 4.4  2.1 lm and +5.4  2.8 lm,
respectively, and are not statistically different from zero.
For SKA-31 responses under the same PE conditions,
average values are 2.5  2.4 lm and +4.4  2.7 lm,
and are not different from zero. However, in the pres-
ence of either 250 nmol/L or 1 lmol/L PE, calculated
mean differences in ACh-evoked dilations are
+16.7  1.7 lm and +22.0  2.4 lm, respectively. In
the case of SKA-31, average differences (i.e., R2–R1) cal-
culated in the presence and absence of 250 nmol/L and
1 lmol/L PE are +14.5  1.3 lm and +17.5  2.6 lm,
respectively. Thus, ACh and SKA-31 evoked statistically
greater dilations in the presence of 250 nmol/L and
1 lmol/L PE, compared with responses in the absence
of PE (P < 0.05). Collectively, these data demonstrate
that VSM a1-adrenoceptor activation functionally aug-
ments endothelium-dependent inhibition of myogenic
tone in a concentration-dependent manner in rat skeletal
muscle arteries.
Similar to ACh and SKA-31, vasodilatory responses
evoked by 10 lmol/L SNP were unchanged in the pres-
ence of bath-applied PE (25 nmol/L and 100 nmol/L),
Figure 2. Quantification of drug-induced changes in intraluminal
diameter in myogenically active cremaster arteries in the absence and
presence of increasing concentrations of phenylephrine (PE). For the
scatter plots shown in panels A, B, and C, each symbol depicts the
relative change, or calculated difference in the magnitude of dilatory
responses (i.e., R2–R1) evoked by a given vasodilator in the absence
(R1) or presence of the indicated concentration of PE (R2), as denoted
by the symbol legend at the top of the figure. Note that each plotted
symbol represents an individual artery. The position of a symbol along
the x-axis reflects the magnitude of PE-induced contraction in
microns (relative to the level of basal myogenic tone) observed for a
given concentration of PE. Experimentally, control dilatory responses
were first obtained following acute bath exposure to ACh (0.3 lmol/
L), SKA-31 (3 lmol/L), and SNP (10 lmol/L) and these responses
were then repeated following bath addition of a fixed concentration
of PE, as shown in Figure 1A. Arteries were typically exposed to only
a single PE concentration during an experiment, followed by washout
to ensure reversibility of PE-induced contraction. Data were collected
from 32-34 arteries, which were isolated from a total of 34 animals.
2018 | Vol. 6 | Iss. 9 | e13703
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as evidenced by the scatter of individual calculated dif-
ferences around the line indicating zero net effect
(Fig. 2C). In the presence of either 250 nmol/L or
1 lmol/L PE, however, the average SNP-evoked vasodi-
lations were modestly, but significantly less than the
control responses (4.8  1.7 lm and 6.2  2.3 lm,
respectively) (Fig. 3). Taken together, these observations
indicate that VSM a1-adrenoceptor activation selectively
enhances vasodilatory responses to the endothelium-
dependent agents ACh and SKA-31 at higher agonist
concentrations, and slightly depresses SNP-evoked
dilation.
The endogenous a-adrenoceptor agonist
norepinephrine augments vasodilatory
responses by endothelium-dependent
agents
As depicted in Figure 4, activation of VSM a-adrenocep-
tors by norepinephrine (NE, 1 lmol/L) produced a simi-
lar degree of vasoconstriction (37.6  7.8 lm) in
myogenically active, cremaster arteries as that seen with
0.25–1 lmol/L PE (Fig. 2). Exposure to NE further aug-
mented the vasodilatory responses to the endothelium-
dependent agents ACh and SKA-31, but not to the
nitrovasodilator SNP, as illustrated by the scatter plot
shown in Figure 4B. Calculated mean differences in dila-
tory responses evoked by 0.3 lmol/L ACh, 3 lmol/L
SKA-31 and 10 lmol/L SNP in the presence and absence
of 1 lmol/L NE are +20.8  1.9 lm, +17.2  2.0 lm
and 7.3  2.5 lm, respectively (values also displayed in
Fig. 3).
Stimulus-evoked vasodilatory responses are
not enhanced by the thromboxane A2
receptor (TP) agonist U46619
To determine if the observed endothelium-dependent
vasodilatory responses could also be augmented by a dif-
ferent vasoconstrictor pathway, we investigated the effects
of TP receptor activation by U46619. In contrast to the
facilitation observed with the a-adrenergic agonists PE
and NE (Figs. 2, 3 and 4), evoked dilations were signifi-
cantly reduced for ACh (11.8  1.7 lm) and SKA-31
(7.2  1.2 lm) and the NO donor SNP
(9.3  2.7 lm) following activation of VSM TP recep-
tors with U46619, compared with control responses
(Figs. 5 and 3). The magnitude of vasoconstriction
induced by 250 nmol/L U46619 in myogenically active
cremaster arteries (51.8  5.1 lm, n = 7) represented
~80% of the maximal U46619-induced contraction (data
not shown) and was comparable to the decreases in intra-
luminal diameter produced by 1 lmol/L PE and 1 lmol/
L NE. These observations indicate that a difference in the
extent of vasoconstrictor-induced tone per se cannot
account for the observed enhancement of endothelium-
evoked dilations by PE and NE, and impairment by
U46619.
The voltage-gated K+ channel blocker 4-
aminopyridine selectively augments
stimulus-evoked dilations
a1-Adrenergic stimulation leads to VSM membrane depo-
larization, which contributes to the contractile response by
directly promoting voltage-dependent, external Ca2+ entry
and elevation of intracellular-free Ca2+ (Miriel et al. 1999;
Mistry and Garland 1999; Zou et al. 2000; Potocnik and
Hill 2001; Li and Janssen 2002; Tran et al. 2012). We thus
hypothesized that membrane depolarization alone may be
sufficient to promote enhancement of endothelium-depen-
dent vasodilation by ACh and SKA-31. To examine this
possibility, myogenically active arteries were exposed to 4-
aminopyridine (4-AP, 1 mmol/L), a nonselective blocker of
voltage-gated K+ channels in VSM(Nelson and Quayle
1995). Functionally, bath application of 4-AP caused a fur-
ther decrease in arterial intraluminal diameter
(37.3  3.1 lm, n = 7) that was consistent with a depolar-
ization-induced elevation of cytosolic Ca2+ in VSM, and
comparable in magnitude to the constrictions produced by
PE, NE and U46619 (Fig. 6). These findings thus agree with
earlier data showing that 4-AP exposure caused both a
Figure 3. Quantification of the average relative changes in evoked
dilation in the absence and presence of vasoconstrictor agonists.
Average differences in the magnitude of evoked vasodilations by
ACh, SKA-31 and SNP (i.e., R2–R1) were calculated from observed
responses in the absence and presence of the vasoconstrictors
denoted beneath the bars. The asterisk (*) denotes a statistically
significant difference in the mean calculated difference relative to
zero, as determined by an unpaired Student’s t test (P < 0.05). For
PE-associated data, average values were calculated from 32-34
arteries; for NE-associated data, 11 arteries were analyzed; for
U46619-associated data, 7 arteries were analyzed. Each artery was
obtained from an individual animal.
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decrease in intraluminal diameter and a membrane depo-
larization in myogenic cerebral arteries from rabbit (Knot
and Nelson 1995). Functionally, 4-AP significantly aug-
mented the vasodilatory response to SKA-31, an activator
of endothelial KCa channels(Sankaranarayanan et al. 2009;
Wulff and K€ohler 2013), but surprisingly, did not produce
a significant enhancement of the ACh response (Fig. 6B).
Under the same conditions, 4-AP also augmented the dila-
tory response to the smooth muscle K-ATP channel activa-
tor pinacidil, which directly relaxes VSM via membrane
hyperpolarization, and a decrease in L-type Ca2+ channel
activity (Nelson and Quayle 1995; Quayle et al. 1997).
Mechanistically, the hyperpolarizing currents (I) generated
in response to either SKA-31 or pinacidil would drive
greater VSM hyperpolarization, due to the increase in VSM
membrane resistance (Rm) induced by 4-AP, as explained
by Ohm’s Law (Vm = I 9 Rm), leading to augmented
relaxation.
a1-Adrenoceptor activation depolarizes VSM
membrane potential and increases
membrane resistance
Observations in the presence of the Kv channel blocker
4-AP prompted us to examine the extent to which a1-
adrenoceptor activation induced membrane depolariza-
tion in cannulated, myogenically active cremaster arteries.
To do so, we performed single microelectrode measure-
ments of VSM membrane potential (Em)  a1-adrenergic
stimulation. In the absence of PE, the steady-state Em of
myogenic arteries pressurized to 60 mmHg was found to
be 33.8  3.2 mV, and addition of 1 lmol/L PE to the
impaled artery led to a further depolarization of Em to
23.5  1.2 mV (P < 0.05 compared with control Em,
n = 4–5 recordings). To determine if the PE-induced Em
depolarization resulted from a decrease in membrane
resistance (Rm), due to the opening of cation-selective ion
Figure 4. Norepinephrine (NE, 1 lmol/L) enhanced responses to ACh and SKA-31, but not SNP in rat cremaster artery. Panel (A) shows a
representative tracing of vasodilatory responses evoked by ACh, SKA-31 and SNP in a myogenic artery in the absence and presence of 1 lmol/
L NE, as indicated by the horizontal bars above and below the tracing. Bath exposure to 0 Ca2+ Krebs’ solution + 2 mmol/L EGTA produced
maximal passive diameter of the artery at 70 mmHg. The scatter plot in panel B quantifies the relative change, or calculated difference in the
magnitude of dilatory responses (i.e., R2–R1) evoked by a given vasodilator in the presence (R2) or absence of 1 lmol/L NE (R1). Individual
symbols represent individual responses to the noted vasodilator, as defined by the legend. The position of a symbol along the x-axis reflects the
magnitude of NE-induced contraction in microns (relative to the level of basal myogenic tone). Data were collected from a total of 11 animals.
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channels in VSM, or an increase in resistance indicative
of VSM K+ channel inhibition, we injected hyperpolariz-
ing current pulses (range = 30–240 pA) via the microelec-
trode to elicit membrane voltage deflections (Fig. 7A and
B). By plotting the magnitude of evoked voltage deflec-
tions versus the size of injected current steps and calculat-
ing Rm from the slopes of the linear relations (i.e.,
R = V/I), we observed that basal VSM membrane resis-
tance significantly increased from 107.3  20.0 MΩ to
186.2  31.2 MΩ in the presence of 1 lmol/L PE
(P < 0.05, n = 4) (Fig. 7C). These findings are thus in
line with earlier studies that have reported basal VSM Rm
values approximating 100 MΩ (Hirst et al. 1986; Yama-
moto et al. 2001), along with increases in Rm following
a1-adrenoceptor activation in arterial VSM (Kajiwara
et al. 1981).
The L-type Ca2+ channel blocker nifedipine
impairs a1-adrenoceptor-mediated
enhancement of endothelium-induced
vasodilation
Activation of a1-adrenoceptors in VSM leads to elevation of
cytosolic Ca2+ via intracellular release and entry via voltage-
gated, L-type Ca2+ channels, and it has been speculated that
this elevated Ca2+ may contribute to PE-mediated enhance-
ment of endothelium-dependent vasodilation (Dora et al.
1997; Yashiro and Duling 2000). To investigate the potential
contribution of L-type Ca2+ channel activity to this phe-
nomenon, we treated myogenically active, cremaster arteries
with nifedipine, an established blocker of L-type Ca2+ chan-
nels, to selectively interfere with Ca2+ signaling in the arterial
smooth muscle. Note that vascular endothelial cells do not
Figure 5. The thromboxane agonist U46619 (250 nmol/L) impairs vasodilatory responses to ACh, SKA-31 and SNP in rat cremaster
artery. Panel A shows a representative tracing of vasodilatory responses evoked by ACh, SKA-31 and SNP in a myogenic cremaster
artery in the absence and presence of 250 nmol/L U46619, as denoted by the horizontal bars above and below the representative
tracing. Following washout (W/O) of U46619, maximal passive diameter at 70 mm Hg was determined in the presence of 0 Ca2+ Krebs’
solution containing 2 mmol/L EGTA. The scatter plot in panel B depicts the relative changes in drug-induced vasodilatory responses for
ACh, SKA-31 and SNP in the presence and absence of 250 nmol/L U46619 (i.e., R2–R1). The position of a symbol along the x-axis
reflects the magnitude of U46619-induced contraction in microns (relative to the level of basal myogenic tone). Data were collected
from a total of 7 animals.
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express L-type Ca2+ channels (Colden-Stanfied et al. 1987;
Adams et al. 1989; Garland et al. 2017). As shown by the
representative tracing in Figure 8A, myogenically active cre-
master arteries exhibited typical dilatory responses to ACh,
SKA-31, and SNP, along with a robust and reversible con-
striction to bath-applied 30 mmol/L KCl (N.B. NaCl in the
Krebs’ buffer was replaced with KCl to maintain isotonicity).
Exposure to 1 lmol/L nifedipine significantly inhibited
myogenic tone, but did not abolish it, in agreement with ear-
lier results (Kotecha and Hill 2005). Nifedipine treatment,
however, largely prevented the contractile response to KCl
(Figs. 8A and B), demonstrating effective blockade of depo-
larization-mediated Ca2+ entry into VSM. Nifedipine also
inhibited contractile responses to PE (25 nmol/L to 1 lmol/
L) (Fig. 8A and 8B), in agreement with the major contribu-
tion of L-type Ca2+ channels to a1-adrenergic-induced vaso-
constriction (Miriel et al. 1999; Moosmang et al. 2003).
Importantly, nifedipine treatment abolished the ability of
1 lmol/L PE to augment vasodilatory responses to ACh and
SKA-31 (Fig. 8C). However, with higher levels of a1-adreno-
ceptor stimulation (i.e. 3 and 10 lmol/L PE), robust con-
strictions were observed in the presence of nifedipine, and
vasodilatory responses to ACh and SKA-31 exhibited mod-
est, but significant augmentation, compared with control
responses obtained in the absence of nifedipine + PE
(Fig. 8A and C). In contrast to these observations, dilatory
responses to SNP in the presence of nifedipine + PE
remained similar to those observed in the presence of
1 lmol/L PE alone (Fig. 8C). Note that under control con-
ditions, we were unable to faithfully record vasoactive
responses in myogenic arteries exposed to either 3 or
10 lmol/L PE alone, as the powerful constrictions prevented
reliable and consistent tracking of intraluminal diameter.
Interestingly, nifedipine exposure did not significantly
Figure 6. The voltage-gated K+ channel blocker 4-aminopyridine (4-AP) augments vasodilatory responses to SKA-31 and pinacidil, activators of
endothelial and smooth muscle K+ channels, respectively. The representative tracing in panel (A) depicts vasodilatory responses to ACh
(0.3 lmol/L), SKA-31 (3 lmol/L), SNP (10 lmol/L) and the K-ATP channel activator pinacidil (3 lmol/L) in both the absence and presence of
1 mmol/L 4-AP, as denoted by the horizontal bars above and below the tracing. Following washout (W/O) of 4-AP, maximal passive diameter
of the artery was determined in the presence of 0 Ca2+ Krebs’ solution + 2 mmol/L EGTA. The histogram in panel B quantifies the average
relative changes in stimulus-evoked dilation (i.e., R2–R1) in the presence (R2) and absence (R1) of 4-AP. Data are presented as mean  SEM for
7 cremaster arteries. The asterisk (*) denotes a statistically significant difference in the magnitude of evoked dilation relative to the control
condition, as determined by an unpaired Student’s t test (P < 0.05).
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impair the constriction induced by 250 nmol/L U46619
(Fig. 8B), indicating only a limited role for
L-typeCa2+channelactivity in thisagonist-evokedresponse.
Augmentation of ACh-evoked
dilation by a1-adrenoceptor
stimulation is blunted by inhibitors
of eNOS and endothelial KCa
channels
Two major Ca2+-dependent signaling pathways in
endothelium contributing to agonist-evoked vasodilation
include the activation of eNOS and the opening of KCa
2.3 and KCa 3.1 channels (Sheng and Braun 2007;
Feletou and Vanhoutte 2009; Sheng et al. 2009). To
examine if either pathway participated in the observed
PE-induced enhancement of endothelium-dependent
dilation, vasodilatory responses to ACh, SNP and SKA-
31 were first examined in the presence of either an inhi-
bitor of eNOS (L-NAME) or blockers of endothelial KCa
channels (i.e. TRAM-34 + UCL-1684), and these
responses were then reexamined following addition of
0.25 lmol/L PE. As shown by the representative tracing
in Figure 9A, exposure of a myogenic cremaster artery to
Baseline
+ 1 µmol/L PE
Control + 1 µmol/L PEA
C
B
Figure 7. Effects of phenylephrine (PE) on VSM membrane resistance in cannulated, myogenically active cremaster arteries. Following
establishment of myogenic tone, a microelectrode was stably impaled in the arterial wall and basal membrane potential (Vm) was recorded.
Three negative, step-wise current injections of increasing magnitude were then applied, as shown by the upper tracing in panel (A). The lower
panel shows the membrane voltage deflections recorded in response to these 2-sec current injections. Panel (B) illustrates the membrane
voltage changes in response to the same series of current injections in the same artery following exposure to 1 lmol/L PE. These tracings are
representative of 4 experiments performed in 3 separate arteries. The graph in panel (C) plots the magnitude of membrane voltage deflections
versus the step size of corresponding current injections. Closed symbols represent Vm deflections observed under basal conditions; open
symbols illustrate measurements made in the presence of 1 lmol/L PE. Straight lines represent a linear regression fit to each set of data points
and the slopes of the lines were used to calculate VSM membrane resistance in MΩ.
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L-NAME alone produced a minor decrease in intralumi-
nal diameter, as we have previously reported(Mishra
et al. 2015), and a significant reduction in the ACh-
evoked dilation, but did not affect vasodilatory responses
to either SKA-31 or SNP. Further addition of 0.25 lmol/
L PE caused a robust constriction that augmented the
vasodilatory response to ACh, as well as SKA-31, whereas
no change was observed for SNP (Fig. 9C). In the pres-
ence of L-NAME, addition of 0.25 lmol/L PE produced
a significant enhancement of the ACh-evoked dilation,
however, the relative magnitude of this vasodilatory
response PE (R2-R1 response = 12.0  1.6 lm,) was
blunted compared with the augmentation of ACh
responses observed without L-NAME treatment
(16.7  1.7 lm, see Fig. 3). In contrast, L-NAME
treatment did not impact the calculated relative change
in the vasodilatory response to SKA-31 in the presence
and absence of 0.25 lmol/L PE (19.6  3.1 lm), which
is comparable to that observed without L-NAME co-
treatment (see Fig. 3). This latter result indicates that
eNOS inhibition does not impact the PE-induced
enhancement of SKA-31 evoked dilation. L-NAME expo-
sure did not alter the dilatory response to SNP (Fig. 9A,
C), which was unaffected by the further addition of
0.25 lmol/L PE.
Treatment of myogenic arteries with blockers of
endothelial KCa 3.1 and KCa 2.3 channels (TRAM-34 and
UCL-1684, respectively) produced a minor vasoconstric-
tion (Mishra et al. 2015) and largely prevented the
vasodilatory response elicited by the KCa channel activator
Figure 8. Calcium entry via nifedipine-sensitive Ca2+ channels is an essential process contributing to PE-induced augmentation of endothelium-
dependent vasodilation. The representative tracing in panel (A) displays vasodilatory responses to 0.3 lmol/L ACh, 3 lmol/L SKA-31 and
10 lmol/L SNP, along with a constrictor response to 30 mmol/L KCl, in a myogenic artery under control conditions, and then following bath
addition of 1 lmol/L nifedipine, as denoted by the horizontal bars above and below the tracing. Addition of either 3 or 10 lmol/L PE in the
continued presence of nifedipine produced significant arterial contraction and reduction in intraluminal diameter. Vasodilatory responses to
ACh, SKA-31 and SNP were then repeated in the presence of nifedipine + PE, followed by washout (W/O) of PE from the bath. The constrictor
response to U46619 was then examined in the continued presence of nifedipine. The histogram in panel (B) quantifies the magnitude of
vasoconstriction induced on top of existing myogenic tone by either 30 mmol/L KCl, PE (25–1000 nmol/L) or 250 nmol/L U46619 in the
absence (control) or presence of 1 lmol/L nifedipine. Data are presented as means  SEM for 6–7 individual arteries. The asterisks (*) indicate
a statistically significant difference compared with the control response, as determined by a Student’s t-test; P < 0.05. Panel (C) quantifies the
relative change in magnitude of vasodilatory response observed for ACh, SKA-31 and SNP in the presence of the indicated concentrations of PE
+ 1 lmol/L nifedipine, relative to control responses in the absence of PE + nifedipine. For reference purposes, the bars on the left-hand side
depict the relative changes in endothelium-dependent dilatory responses observed in the presence of 1 lmol/L PE alone. The * indicates that a
given value is statistically different from zero, as determined by a Student’s t-test.
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SKA-31, as one would anticipate (Fig. 9B). Further addi-
tion of 0.25 lmol/L PE in the presence of the KCa channel
blockers did not alter the magnitude of the SKA-31 induced
dilation (Fig. 9D), indicating an absence of PE-induced
augmentation. Exposure to TRAM-34 + UCL-1684 also
blunted the ACh-evoked dilation (Fig. 9B), and the modest
change in response observed following addition of PE
(R2–R1 response = 5.8  2.4 lm) was not statistically
significant (Fig. 9D).
Discussion
The intraluminal diameter of resistance arteries is a criti-
cal determinant of systemic blood pressure and blood
flow distribution within tissues, and is regulated, in part,
by the extent of luminal pressure-induced myogenic tone.
Sympathetic innervation and stimulation of resistance
arteries can lead to further constriction, via activation of
smooth muscle a-adrenoceptors (Westcott and Segal
A
B
C D
Figure 9. Pharmacologic inhibition of either eNOS or endothelial KCa channels blocks PE-induced augmentation of evoked vasodilation.
Panel (A) shows a representative tracing of vasodilatory responses evoked by ACh, SKA-31 and SNP in a myogenic artery under control
conditions, in the presence of the eNOS inhibitor L-NAME (0.1 mmol/L), and then in the presence of L-NAME + of 0.25 lmol/L PE, as indicated
by the horizontal bars above and below the tracing. Bath exposure to 0 Ca2+ Krebs’ solution + 2 mmol/L EGTA produced maximal passive
diameter of the artery at 70 mmHg. In panel (B), vasodilatory responses to ACh, SKA-31 and SNP were observed in the absence and presence
of the endothelial KCa channel blockers TRAM-34 (1 lmol/L) + UCL-1684 (0.5 lmol/L), followed by TRAM-34 + UCL-1684 + 0.25 lmol/L PE.
The histograms in panels (C) and (D) quantify the absolute changes in intraluminal diameter evoked by ACh, SNP and SKA-31 for treatments
involving either L-NAME (panel C) or TRAM-34 + UCL-1684 (panel D). Data are presented as means  SEM for 3 individual arteries for each
protocol. The asterisk (*) indicates a statistically significant difference compared with the control response for a given dilatory agent; the cross
symbol (†) indicates a significant difference versus responses observed in the presence of either L-NAME or TRAM-34 + UCL1684 alone.
Statistical analyses were performed using a one-way ANOVA and Tukey’s post hoc test; P < 0.05.
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2013), whereas locally generated vasodilators (e.g., nitric
oxide, endothelium-derived hyperpolarization) oppose
contractile processes. Several reports have demonstrated
that a1-adrenergic stimulation of vascular smooth muscle
(VSM) can positively influence the effectiveness of
endothelium-evoked vasodilation in peripheral resistance
arteries, and at a cellular level, this phenomenon is associ-
ated with a rise in endothelial free Ca2+ (Dora et al. 1997,
2003; Yashiro and Duling 2000; Nausch et al. 2012; Gar-
land et al. 2017). In this study, we independently repro-
duce and expand these observations by describing a
systematic characterization of VSM a1-adrenoceptor-
dependent modulation of endothelium-mediated vasodila-
tion in isolated, myogenically active resistance arteries
from rat cremaster muscle. Our findings demonstrate that
the a1-adrenoceptor-driven augmentation of endothe-
lium-dependent vasodilatory responses requires a thresh-
old concentration of a1-adrenergic agonist, and occurs in
a positive fashion suggestive of increasing a1-adrenoceptor
occupancy/activation (see Figs. 1 and 2). Physiologically,
this influence of a1-adrenoceptor activity on endothe-
lium-mediated vasodilation would act in a negative feed-
back fashion to limit a1-adrenergic-induced decreases in
intraluminal diameter of resistance arteries that may arise
with augmented levels of sympathetic nerve activity. Lim-
iting such constriction would prevent restrictions and/or
dysregulation in tissue blood flow and excessive rises in
systemic blood pressure.
Experimentally, it is evident from the tracing in Fig-
ure 1 and the cumulative data in Figures 2 and 3 that the
a1-adrenergic agonist phenylephrine (PE) acts in a con-
centration-dependent manner to enhance the endothe-
lium-dependent vasodilatory responses evoked by the
Ca2+-mobilizing agonist acetylcholine (ACh) and SKA-31,
a small molecule activator of endothelial Ca2+-activated
K+ channels (i.e. KCa 2.3 and KCa 3.1) (Sankaranarayanan
et al. 2009). By utilizing the magnitude of PE-induced
contraction as a functional correlate of a1-adrenoceptor
activation, it is apparent from Figures 3 and 4 that a pos-
itive relation exists between the degree of a1-adrenergic
stimulation and the enhancement of endothelium-depen-
dent vasodilation, recapitulating the hypothesized relation
presented in Figure 1B. Denuding the vascular endothe-
lium is known to prevent this enhancement of vasodila-
tory responses by a1-adrenoceptor stimulation (Dora
et al. 1997; Garland et al. 2017). In contrast to ACh and
SKA-31, exposure to PE blunted the dilatory response to
the nitrovasodilator sodium nitroprusside (SNP), which is
known to act directly on VSM to cause relaxation via a
NO/cGMP/PKG signaling cascade (Feelisch 1998). Func-
tionally, the positive and negative actions of PE on the
vasodilatory actions of ACh, SKA-31 and SNP were mim-
icked by the native adrenoceptor agonist norepinephrine
(1 lmol/L, Figs. 3 and 4). Earlier work has demonstrated
that the a1-adrenoceptor is the predominant subtype in
the rat vessels utilized in this study (i.e. cremaster 1A
arteries)(Faber 1988; Ohyanagi et al. 1991; Moore et al.
2010a), and that NE-induced vasoconstriction in these
arteries is largely blocked by the a1-adrenergic antagonist
prazosin, but not by the a2-adrenoceptor antagonist rau-
wolscine. In murine cremaster arteries, inhibition of
b-adrenoceptors with propranolol was found to have no
effect on either PE or NE-induced vasoconstriction
(Moore et al. 2010a), implying that these agonists act lar-
gely via a-adrenoceptors in cremaster arteries. Collec-
tively, these observations point to a major contribution of
endothelium and VSM a1-adrenoceptors to the PE and
NE-induced enhancement of evoked vasodilation. Inter-
estingly, our data further imply that the rise in VSM Ca2+
observed in myogenically active resistance arteries at
physiologic pressures (e.g., 70 mmHg) (Meininger et al.
1991; Zou et al. 2000) is insufficient to promote enhance-
ment of endothelium-dependent vasodilation, as we
observed no difference in evoked vasodilatory responses
in the absence and presence of a low concentration of PE
(i.e., 25 and 100 nmol/L), even though this latter condi-
tion increased contraction and is reported to elevate
cytosolic-free Ca2+ in cremaster VSM (Potocnik and Hill
2001). Mechanistically, Dora and colleagues have sug-
gested that enhancement of endothelium-dependent
vasodilation via VSM signaling requires the recruitment
of additional L-type Ca2+ channels in VSM, as Ca2+ entry
due solely to myogenic mechano-transduction may be
compartmentalized from the Ca2+ signaling underlying
augmentation of endothelium-dependent dilation (Gar-
land et al. 2017).
In contrast to the enhancement observed with a1-adre-
nergic stimulation, exposure of myogencially active arter-
ies to the thromboxane A2 receptor (TP) agonist U46619
(250 nmol/L) significantly impaired dilatory responses to
ACh, SKA-31 and SNP, despite producing a degree of
constriction comparable to that observed in the presence
of either 1 lmol/L PE or 1 lmol/L NE (Figs. 4 and 6).
This differential response likely reflects the prominent role
played by Ca2+ sensitization of the VSM contractile
machinery in the TP receptor-induced vasoconstriction
and less dependence on evoked Ca2+ dynamics (Himpens
et al. 1990; Tosun et al. 1998; Wilson et al. 2005). If
elevations in VSM Ca2+ represent a critical step in the cel-
lular mechanism driving enhancement of endothelium-
dependent vasodilatory responses, then other stimulatory
events that elevate cytosolic Ca2+ in VSM may augment
these responses in a manner comparable to a1-adrenocep-
tor activation. 4-Aminopyridine (4-AP) is an established
blocker of voltage-gated K+ channels in VSM that pro-
duces membrane depolarization and promotes
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contraction via the opening of L-type Ca2+ channels
(Knot and Nelson 1995; Nelson and Quayle 1995). Expo-
sure of myogenically active cremaster arteries to 1 mmol/
L 4-AP produced a robust constriction comparable to
those observed with PE and NE, and significantly aug-
mented the vasodilatory response to SKA-31. In line with
observations for PE and NE, 4-AP did not alter the dila-
tory response to SNP (Fig. 6). Surprisingly, 4-AP did not
significantly enhance the ACh-induced vasodilation. This
observation likely reflects the reported ability of 4-AP
(0.1–3 mmol/L) to interact directly with muscarinic
receptors to impair ligand binding (Lai et al. 1985). 4-AP
binding to muscarinic receptors in the heart also activates
K+ currents in cardiac pacemaker cells (Navarro-Polanco
and Sanchez-Chapula 1997; Arechiga-Figueroa et al.
2010). As a result of these 4-AP/receptor interactions, the
ability of ACh to activate endothelial muscarinic receptors
was possibly compromised in the presence of 1 mmol/L
4-AP, thereby reducing the efficacy of ACh-mediated
vasodilation (e.g., effective receptor occupancy by ACh
reduced from 50 to 60% to a lower level) and preventing
full expression of the a1-adrenergic-induced enhancement.
Recently, Jepps and colleagues have reported that 4-AP
caused relaxation of NE-contracted rat mesenteric arter-
ies, and that this action could be prevented by blockers of
Kv7.4 and BKCa currents (Khammy et al. 2018). Although
4-AP typically produces constriction, not relaxation of
myogenic arteries (e.g., see Fig. 6, Telezhkin et al. (2007)
and Kang et al. (2009)), these findings suggest that 4-AP
may have additional effects that could limit the augmen-
tation of ACh-induced dilation. It is also noteworthy that
4-AP treatment enhanced the vasodilation evoked by
pinacidil (3 lmol/L), an opener of ATP-sensitive K+
channels prominently expressed in VSM. By directly acti-
vating K+ channels, SKA-31 and pinacidil stimulate
hyperpolarizing membrane currents in vascular endothe-
lium and smooth muscle, respectively, which ultimately
cause VSM hyperpolarization. Given this action, it is not
perhaps surprising that these agents evoke greater
vasodilatory responses in 4-AP-treated myogenic arteries
that exhibit greater membrane resistance and depolariza-
tion, relative to arteries experiencing only pressure-
induced myogenic constriction.
Similar to 4-AP, a1-adrenergic stimulation also pro-
duced membrane depolarization in myogenically con-
tracted cremaster arteries that was associated with a
significant rise in membrane electrical resistance (Fig. 7).
This observation is thus consistent with earlier reports
describing the inhibition of outward K+ currents in vas-
cular smooth muscle by a1-adrenergic agonists, such as
PE (Bonev and Nelson 1996; Mistry and Garland 1999; Li
and Janssen 2002). As predicted by Ohm’s Law
(V = I 9 R), an increase in steady-state membrane
resistance would allow for a greater change in membrane
potential for a given amount of current crossing the VSM
membrane. Mechanistically, this observation implies that
a fixed amount of hyperpolarizing current traveling from
the endothelium to the adjacent smooth muscle would
generate an increasingly larger hyperpolarization in VSM
as membrane resistivity rises. Thus, enhancement of SKA-
31-mediated vasodilation in the presence of a1-adreno-
ceptor activation may result from a modest rise in
endothelial KCa channel activity, due to elevated cytosolic
Ca2+, along with an increase in VSM membrane resis-
tance. In combination, these two factors would lead to an
augmented hyperpolarization of the VSM that would
dampen voltage-gated Ca2+ channel activity, Ca2+ entry
and VSM contractility.
Voltage-gated, L-type Ca2+ channels are known to play
an important role in pressure-induced myogenic constric-
tion and a1-adrenoceptor-evoked contractile responses
(Davis and Hill 1999; Hill et al. 2001; Kotecha and Hill
2005), but their functional importance for the a1-adrener-
gic-mediated augmentation of endothelium-mediated
vasodilation remains poorly understood. The data in Fig-
ure 8 demonstrate that blockade of L-type Ca2+ channels
with the classic dihydropyridine inhibitor nifedipine
(1 lmol/L) effectively abolished the contractile response
of myogenic arteries to 30 mmol/L KCl and strongly
attenuated the constriction evoked by 1 lmol/L PE; col-
lectively, these contractility data strongly imply that
nifedipine treatment prevented a rise in VSM cytosolic
Ca2+ to support KCl and PE-stimulated contractions.
Critically, the presence of nifedipine changed the effect of
1 lmol/L PE on endothelium-mediated vasodilation from
positive to negative (Fig. 8C). However, the a1-adreno-
ceptor-mediated enhancement could be functionally
restored by exposing nifedipine-treated arteries to higher
concentrations of PE (i.e., 3 and 10 lmol/L) that gener-
ated considerable vasoconstriction; this latter observation
would be consistent with increasing levels of VSM cytoso-
lic Ca2+ (Potocnik and Hill 2001; Garland et al. 2017).
Mechanistically, these putative Ca2+ elevations could arise
from internal Ca2+ store release and/or external Ca2+
entry via nifedipine-insensitive channels or transporters.
Taken together, these data indicate that L-type Ca2+ chan-
nels contribute not only to the normal a1-adrenoceptor-
induced vasoconstriction in myogenically active cremaster
arteries, but also to the a1-adrenergic-mediated augmen-
tation of endothelium-dependent vasodilatory responses,
which is in agreement with the findings of Dora and
coworkers (Garland et al. 2017). Reduction in L-type
channel activity decreases the efficacy with which a1-adre-
noceptor stimulation triggers augmentation of endothe-
lium-mediated vasodilation, most likely by eliminating a
major pathway for Ca2+ elevation in VSM.
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Mechanistically, augmentation of endothelial Ca2+ sig-
naling in the presence of PE could impact the activation
of both eNOS and endothelial KCa channels by Ca
2+-
mobilizing vasodilators (e.g., ACh). Selective inhibition of
eNOS activity with L-NAME significantly decreased the
PE-induced enhancement of ACh-evoked vasodilation,
and a similar effect was observed in the presence of the
KCa channel blockers TRAM-34 + UCL-1684 (Fig. 9).
These data strongly suggest that the activities of both
eNOS and endothelial KCa 2.3 and KCa 3.1 channels par-
ticipate in the observed augmentation of agonist-evoked
dilation in the presence of PE, which would agree with
their known Ca2+ sensitivity. At the cellular level, we have
observed that endothelial KCa channel activity is impor-
tant for agonist-evoked NO synthesis (Sheng and Braun
2007) and augmentation of KCa 2.3 and KCa 3.1 currents
promotes greater endothelial hyperpolarization (Sheng
et al. 2009). Similarly, Dora and colleagues have reported
that pharmacologic inhibition of KCa 2.3 and KCa 3.1
channels interfered with the PE-induced augmentation of
endothelium-dependent regulation of myogenic tone in
cremaster arteries (Garland et al. 2017).
The schematic in Figure 10 highlights the major cellu-
lar events/pathways implicated in the a1-adrenergic
enhancement of endothelium-mediated vasodilation in
skeletal muscle resistance arteries. Mechanistically, pres-
sure-induced depolarization of VSM acts as the primary
stimulus for elevation of cytosolic Ca2+ via voltage-gated
Ca2+ channels and the initiation of myogenic contraction
(Davis and Hill 1999; Hill et al. 2001), which can be fur-
ther increased by a superimposed stimulus that also ele-
vates VSM Ca2+ (e.g., a1-adrenoceptor agonist). As the
secondary stimulus elevates cytosolic Ca2+ beyond a
threshold level, or possibly in a distinct subcellular com-
partment, a parallel rise in endothelial Ca2+ is initiated,
likely by the gradient-driven diffusion of VSM Ca2+ and/
or the transcellular movement of a Ca2+ mobilizing sec-
ond messenger, such as IP3 (Isakson et al. 2007; Nausch
et al. 2012), via gap junction channels located at myoen-
dothelial connections between the two cell types (Sandow
et al. 2006; Straub et al. 2014). Elevated endothelial Ca2+
would then enhance the actions of endothelium-depen-
dent, Ca2+ mobilizing vasodilatory stimuli (e.g. ACh) that
elicit KCa 2.3 and/or KCa 3.1 channel-mediated hyperpo-
larizing K+ currents and nitric oxide production that act
on the adjacent VSM to dampen contraction. In support,
other investigators have provided compelling evidence
that a1-adrenergic stimulation of skeletal muscle resis-
tance arteries can elevate endothelial cell (EC) free Ca2+
and augment endothelium-dependent vasodilation (Dora
et al. 1997; Yashiro and Duling 2000; Tran et al. 2012;
Garland et al. 2017). In isolated mouse mesenteric arter-
ies, Nausch and colleagues (Nausch et al. 2012). have
reported similar observations following electrical nerve
stimulation or direct application of PE. Importantly, Dora
and colleagues have demonstrated that elevation of
endothelial cell free Ca2+ by PE in rat cremaster arteries
is blocked in the presence of nifedipine (Garland et al.
2017). These investigators have further shown that
endothelial KCa channels are important targets for PE-
induced elevations in endothelial Ca2+, as inhibition of
these channels prevented the enhanced vasodilation
observed in the presence of PE (Garland et al. 2017). This
conclusion thus agrees with the observed PE-induced
Figure 10. Cartoon summarizing the putative cellular processes
contributing to a1-adrenoceptor-mediated enhancement of
endothelium-dependent vasodilation in skeletal muscle resistance
arteries. Elevation of intraluminal pressure promotes vascular
smooth muscle cell (VSMC) depolarization, activation of L-type,
voltage-gated Ca2+ channels (VGCCs) and Ca2+ entry. The rise in
cytosolic-free Ca2+ then drives myofilament-based contraction and
a reduction in intraluminal diameter. Release of norepinephrine
from perivascular sympathetic nerves stimulates a1-adrenoceptors
(a1-ARs) on the VSMC membrane, leading to IP3-mediated Ca
2+
release from the sarcoplasmic reticulum (SR) and VGCC activation
via membrane depolarization, both of which augment cytosolic-free
Ca2+ and promote contraction. As the level of VSM cytosolic Ca2+
rises with increasing a1-adrenoceptor stimulation and passes a
critical threshold, further rises in VSM Ca2+ lead to diffusion of
cytosolic Ca2+ and/or IP3 from the VSM to the adjacent vascular
endothelium via myoendothelial junctions (MEJ). Elevation of
endothelial cell free Ca2+ augments the initial activation of eNOS
and Ca2+-activated K+ channels (KCa) by vasodilatory stimuli. The
enhanced opening of endothelial KCa channels generates a more
robust hyperpolarizing current that travels back to the VSM via
MEJs to cause VSM hyperpolarization, a reduction in VGCC activity
and cytosolic-free Ca2+, thereby limiting the magnitude of
contraction. The main cellular events underlying this a1-
adrenoceptor-driven, negative feedback process are highlighted in
red.
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augmentation of SKA-31 mediated dilation described in
our study. Elevation of VSM Ca2+ via a1-adrenergic sig-
naling is thus capable of initiating a negative feedback
mechanism that recruits the adjacent endothelium and
serves as a “brake” to limit the magnitude of stimulus-
evoked VSM contraction in skeletal muscle resistance
arteries (highlighted by red shading in the schematic).
We speculate that the observed feedback regulation of
VSM contractility by endothelium-dependent signaling in
a1-stimulated skeletal muscle resistance arteries con-
tributes to “functional sympatholysis”, a phenomenon in
which sympathetic vasoconstriction in exercising skeletal
muscle exhibits attenuation (Remensnyder et al. 1962),
thereby allowing blood flow to match metabolic demand
(Hansen et al. 2000). Functional sympatholysis has been
described in the vasculature of rodent and human skeletal
muscle (VanTeeffelen and Segal 2003; Moore et al. 2010b;
Hearon and Dinenno 2016; Hearon et al. 2016), and may
impact both local dilatory responses and conducted
vasodilation in skeletal muscle. In addition, our data sug-
gest that a low level of a1-adrenoceptor activation would
promote/support the elevated vascular resistance to blood
flow typically observed in resting skeletal muscle (Saltin
et al. 1998), which would then “flip” to enhance active
vasodilation once a “threshold” level of a1-adrenergic
stimulation is attained (Fig. 2A). Finally, our findings
may have important implications for the regulation of
blood flow and blood pressure under conditions involving
endothelial dysfunction (e.g., type 2 diabetes. ageing).
Impairment of endothelial function may compromise the
robustness of the observed a1-adrenoceptor-driven nega-
tive feedback pathway, thereby limiting the capacity of
resistance arteries in exercising muscle to dilate in the face
of elevated sympathetic tone. This deficit could thus com-
promise the pattern and/or volume of blood flow in the
skeletal circulation by maintaining arteries in an overcon-
stricted state (Saltin and Mortensen 2012; Hearon and
Dinenno 2016), and possibly lead to elevated systemic
blood pressure. Similar consequences would be predicted
in other vascular beds (e.g., mesentery) exhibiting a1-
adrenoceptor-mediated enhancement of endothelium-
dependent vasodilation (Nausch et al. 2012).
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